Financhill
Sell
50

IRTC Quote, Financials, Valuation and Earnings

Last price:
$142.93
Seasonality move :
6.56%
Day range:
$139.07 - $144.25
52-week range:
$55.92 - $144.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.23x
P/B ratio:
52.56x
Volume:
347K
Avg. volume:
536.1K
1-year change:
62.07%
Market cap:
$4.6B
Revenue:
$591.8M
EPS (TTM):
-$3.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IRTC
iRhythm Technologies
$153.4M -$0.94 17.49% -27.01% $140.42
ATRC
AtriCure
$122.9M -$0.22 11.96% -4.31% $49.89
ISRG
Intuitive Surgical
$2.2B $1.73 16.8% 32.43% $575.78
MASI
Masimo
$367.8M $1.21 -25.72% 321.55% $182.07
PODD
Insulet
$543.3M $0.79 25.32% -63.95% $328.73
RMD
ResMed
$1.3B $2.36 8.17% 24.05% $264.49
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IRTC
iRhythm Technologies
$142.69 $140.42 $4.6B -- $0.00 0% 7.23x
ATRC
AtriCure
$32.71 $49.89 $1.6B -- $0.00 0% 3.21x
ISRG
Intuitive Surgical
$539.54 $575.78 $193.4B 79.11x $0.00 0% 22.47x
MASI
Masimo
$150.13 $182.07 $8.1B 116.80x $0.00 0% 4.13x
PODD
Insulet
$321.36 $328.73 $22.6B 57.80x $0.00 0% 10.81x
RMD
ResMed
$242.84 $264.49 $35.6B 27.25x $0.53 0.87% 7.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IRTC
iRhythm Technologies
88.19% 0.908 19.37% 5.40x
ATRC
AtriCure
11.98% 2.163 3.87% 2.67x
ISRG
Intuitive Surgical
-- 1.838 -- 3.81x
MASI
Masimo
40.75% 1.411 7.21% 0.87x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
RMD
ResMed
10.82% 0.505 2.05% 1.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IRTC
iRhythm Technologies
$109.2M -$32.6M -13.41% -112.03% -17.37% -$17.3M
ATRC
AtriCure
$92.6M -$6M -7.31% -8.3% -4.12% -$13.2M
ISRG
Intuitive Surgical
$1.5B $578.1M 15.82% 15.82% 25.66% $465M
MASI
Masimo
$234M $80.7M -24.62% -39.91% 20.75% $27M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
RMD
ResMed
$766.4M $426.3M 22.47% 25.76% 33% $554.9M

iRhythm Technologies vs. Competitors

  • Which has Higher Returns IRTC or ATRC?

    AtriCure has a net margin of -19.35% compared to iRhythm Technologies's net margin of -5.46%. iRhythm Technologies's return on equity of -112.03% beat AtriCure's return on equity of -8.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    ATRC
    AtriCure
    74.93% -$0.14 $516.5M
  • What do Analysts Say About IRTC or ATRC?

    iRhythm Technologies has a consensus price target of $140.42, signalling downside risk potential of -1.59%. On the other hand AtriCure has an analysts' consensus of $49.89 which suggests that it could grow by 52.52%. Given that AtriCure has higher upside potential than iRhythm Technologies, analysts believe AtriCure is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    ATRC
    AtriCure
    5 0 0
  • Is IRTC or ATRC More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison AtriCure has a beta of 1.571, suggesting its more volatile than the S&P 500 by 57.127%.

  • Which is a Better Dividend Stock IRTC or ATRC?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AtriCure offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. AtriCure pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or ATRC?

    iRhythm Technologies quarterly revenues are $158.7M, which are larger than AtriCure quarterly revenues of $123.6M. iRhythm Technologies's net income of -$30.7M is lower than AtriCure's net income of -$6.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while AtriCure's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.23x versus 3.21x for AtriCure. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    7.23x -- $158.7M -$30.7M
    ATRC
    AtriCure
    3.21x -- $123.6M -$6.7M
  • Which has Higher Returns IRTC or ISRG?

    Intuitive Surgical has a net margin of -19.35% compared to iRhythm Technologies's net margin of 30.99%. iRhythm Technologies's return on equity of -112.03% beat Intuitive Surgical's return on equity of 15.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    ISRG
    Intuitive Surgical
    64.69% $1.92 $17.2B
  • What do Analysts Say About IRTC or ISRG?

    iRhythm Technologies has a consensus price target of $140.42, signalling downside risk potential of -1.59%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 6.72%. Given that Intuitive Surgical has higher upside potential than iRhythm Technologies, analysts believe Intuitive Surgical is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    ISRG
    Intuitive Surgical
    14 10 1
  • Is IRTC or ISRG More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

  • Which is a Better Dividend Stock IRTC or ISRG?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or ISRG?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. iRhythm Technologies's net income of -$30.7M is lower than Intuitive Surgical's net income of $698.4M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 79.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.23x versus 22.47x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    7.23x -- $158.7M -$30.7M
    ISRG
    Intuitive Surgical
    22.47x 79.11x $2.3B $698.4M
  • Which has Higher Returns IRTC or MASI?

    Masimo has a net margin of -19.35% compared to iRhythm Technologies's net margin of -45.89%. iRhythm Technologies's return on equity of -112.03% beat Masimo's return on equity of -39.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    MASI
    Masimo
    62.9% -$3.17 $1.6B
  • What do Analysts Say About IRTC or MASI?

    iRhythm Technologies has a consensus price target of $140.42, signalling downside risk potential of -1.59%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 21.28%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    MASI
    Masimo
    4 3 0
  • Is IRTC or MASI More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock IRTC or MASI?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or MASI?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Masimo quarterly revenues of $372M. iRhythm Technologies's net income of -$30.7M is higher than Masimo's net income of -$170.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.23x versus 4.13x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    7.23x -- $158.7M -$30.7M
    MASI
    Masimo
    4.13x 116.80x $372M -$170.7M
  • Which has Higher Returns IRTC or PODD?

    Insulet has a net margin of -19.35% compared to iRhythm Technologies's net margin of 6.22%. iRhythm Technologies's return on equity of -112.03% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About IRTC or PODD?

    iRhythm Technologies has a consensus price target of $140.42, signalling downside risk potential of -1.59%. On the other hand Insulet has an analysts' consensus of $328.73 which suggests that it could grow by 2.29%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    PODD
    Insulet
    14 2 0
  • Is IRTC or PODD More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock IRTC or PODD?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or PODD?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Insulet quarterly revenues of $569M. iRhythm Technologies's net income of -$30.7M is lower than Insulet's net income of $35.4M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Insulet's PE ratio is 57.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.23x versus 10.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    7.23x -- $158.7M -$30.7M
    PODD
    Insulet
    10.81x 57.80x $569M $35.4M
  • Which has Higher Returns IRTC or RMD?

    ResMed has a net margin of -19.35% compared to iRhythm Technologies's net margin of 28.26%. iRhythm Technologies's return on equity of -112.03% beat ResMed's return on equity of 25.76%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    RMD
    ResMed
    59.33% $2.48 $6.2B
  • What do Analysts Say About IRTC or RMD?

    iRhythm Technologies has a consensus price target of $140.42, signalling downside risk potential of -1.59%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.92%. Given that ResMed has higher upside potential than iRhythm Technologies, analysts believe ResMed is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    RMD
    ResMed
    8 6 1
  • Is IRTC or RMD More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

  • Which is a Better Dividend Stock IRTC or RMD?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. iRhythm Technologies pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IRTC or RMD?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than ResMed quarterly revenues of $1.3B. iRhythm Technologies's net income of -$30.7M is lower than ResMed's net income of $365M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while ResMed's PE ratio is 27.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.23x versus 7.13x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    7.23x -- $158.7M -$30.7M
    RMD
    ResMed
    7.13x 27.25x $1.3B $365M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock